Fig. 2.

Correlation between change from REGAIN baseline to week 26, in Neuro-QOL Fatigue subscale total score and a MG-ADL, b QMG, and c MG-QOL15 total scores by treatment group (eculizumab, n = 54; placebo, n = 58). Improvements in Neuro-QOL Fatigue total score correlated with improvements in a MG-ADL, b QMG, and c MG-QOL15 total scores more strongly in patients treated with eculizumab than in those who received placebo. Within treatment arms, the null hypothesis was r = 0.4 (the lower limit for moderate correlations). CI confidence interval, MG-ADL Myasthenia Gravis-Activities of Daily Living, MG-QOL15 15-item Myasthenia Gravis Quality of Life, Neuro-QOL Fatigue Quality of Life in Neurological Disorders Fatigue subscale, QMG quantitative myasthenia gravis